Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications

  • Kang, Elise (Division of Pediatric Gastroenterology, Hepatology and Nutrition, University Hospitals/Rainbow Babies & Children's Hospital) ;
  • Khalili, Ali (Division of Pediatric Gastroenterology, Hepatology and Nutrition, University Hospitals/Rainbow Babies & Children's Hospital) ;
  • Splawski, Judy (Division of Pediatric Gastroenterology, Hepatology and Nutrition, University Hospitals/Rainbow Babies & Children's Hospital) ;
  • Sferra, Thomas J. (Division of Pediatric Gastroenterology, Hepatology and Nutrition, University Hospitals/Rainbow Babies & Children's Hospital) ;
  • Moses, Jonathan (Division of Pediatric Gastroenterology, Hepatology and Nutrition, University Hospitals/Rainbow Babies & Children's Hospital)
  • Received : 2017.07.24
  • Accepted : 2018.02.21
  • Published : 2018.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.

Keywords

References

  1. Cuffari C, Darbari A. Inflammatory bowel disease in the pediatric and adolescent patient. Gastroenterol Clin North Am 2002;31:275-91. https://doi.org/10.1016/S0889-8553(01)00017-6
  2. Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-9. https://doi.org/10.1111/j.1365-2036.2011.04599.x
  3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance in- fliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. https://doi.org/10.1016/S0140-6736(02)08512-4
  4. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. https://doi.org/10.1056/NEJMoa050516
  5. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009;15:1264-75. https://doi.org/10.1002/ibd.20899
  6. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. https://doi.org/10.1056/NEJMoa020888
  7. Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Vipul J, et al. Incidence, prevention and management of anti-drug antibodies against ther- apeutic antibodies in inflammatory bowel disease: a practical overview. Drugs 2017;77:363-77. https://doi.org/10.1007/s40265-017-0693-5
  8. Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical use of infliximab concentration monitoring in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2016;62:715-22. https://doi.org/10.1097/MPG.0000000000001029
  9. Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012;382:177-88. https://doi.org/10.1016/j.jim.2012.06.002
  10. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7. https://doi.org/10.1038/ajg.2008.88
  11. Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut 2016;65: 1126-31. https://doi.org/10.1136/gutjnl-2014-307882
  12. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013;108: 40-7; quiz 48. https://doi.org/10.1038/ajg.2012.363
  13. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71. https://doi.org/10.1038/ajg.2013.12
  14. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95. https://doi.org/10.1056/NEJMoa0904492
  15. Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3. https://doi.org/10.1053/j.gastro.2013.10.052
  16. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015;64:1539-45. https://doi.org/10.1136/gutjnl-2014-307883
  17. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 2017; 153:827–34. https://doi.org/10.1053/j.gastro.2017.07.032
  18. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148: 1320-29. https://doi.org/10.1053/j.gastro.2015.02.031
  19. Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, et al. Effects of transient and persistent anti-drug antibodies to certolizuman pegol: longitudinal data from a 7-year study in Crohn's disease. Inflamm Bowel Dis 2017;23:1047-56. https://doi.org/10.1097/MIB.0000000000001100

Cited by

  1. Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease vol.11, pp.None, 2018, https://doi.org/10.3389/fimmu.2020.01148